In a recent decision, a district court in the District of
Delaware applied estoppel under 35 U.S.C. § 315(e)(2) to a
defendant in Hatch-Waxman litigation, two and half years after the
court conducted a bench trial on validity. See Novartis Pharm. Corp. v.
Par Pharm. Inc., No. 14-1289-RGA, ECF No. 198 (D. Del.
Apr. 11, 2019) ("Slip Op.").
Between October 2014 and January 2015, Novartis filed three
suits against Par for its submission of Abbreviated New Drug
Applications ("ANDAs") seeking FDA approval of generic
versions of Novartis's ZORTRESS® (everolimus) and
AFINITOR® (everolimus) tablets. Novartis also sued Breckenridge
and West-Ward for their ANDA filings relating to everolimus
tablets. The defendants stipulated to infringement of the asserted
U.S. Patent No. 5,665,772 ("the '772 patent"), but
contested the validity of asserted claims 1-3, 7, and 10 in a
four-day bench trial in late August and early September of 2016,
raising invalidity challenges including